참고문헌
- Anderson F, Jatoi I, Tse J, Rosenberg S (2010). Male breast cancer: A population-based comparison with female breast cancer. J Clin Oncol, 28, 232-9. https://doi.org/10.1200/JCO.2009.23.8162
- ASCO Working Group on Genetic Testing for Cancer Susceptibility: American Society of Clinical Oncology Policy Statement Update: geneting testing for cancer Susceptibility. (2007) J Clin Oncol, 21, 2397-406.
- Bergh J, Jonsson P, Glimelius B, Nygren P (2001). A systematic overview of chemotherapy effects in breast cancer, Acta Oncol, 40, 253-81. https://doi.org/10.1080/02841860151116349
- Boughey J, Bedrosian I, Meric-Bernstam F, et al (2006). Comparative analysis of sentinel lymph node operation in male and female breast cancer patients, J Am Coll Surg, 203, 475-80. https://doi.org/10.1016/j.jamcollsurg.2006.06.014
- Brinton A, Richesson A, Gierach L, et al (2008). Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst, 100, 1477-81. https://doi.org/10.1093/jnci/djn329
- Buzdar A, Ibrahim N, Francis D, et al (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer, J Clin Oncol, 23, 3676-85. https://doi.org/10.1200/JCO.2005.07.032
- Chianakwalam C, McCahy P, Griffiths N (2005). A case of male breast cancer in association with bicalutamide-induced gynaecomastia, Breast, 14, 163-4. https://doi.org/10.1016/j.breast.2004.04.007
- Cimmino V, Degnim A, Sabel M, et al (2004), Efficacy of sentinel lymph node biopsy in male breast cancer, J Surg Oncol, 86, 74-7. https://doi.org/10.1002/jso.20045
- Clarke M, Collins R, Darby S, et al (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials, Lancet, 366, 2087-106. https://doi.org/10.1016/S0140-6736(05)67887-7
- Coard K, McCartney T (2004). Bilateral synchronous carcinoma of the male breast in a patient receiving estrogen therapy for carcinoma of the prostate: cause or coincidence? South Med J, 97, 308-10. https://doi.org/10.1097/01.SMJ.0000050686.54786.79
- Contractor B, Kaur K, Rodrigues S, Kulkarni M, Singhal H (2008). Male breast cancer: is the scenario changing. World J Surg Oncol, 6, 58. https://doi.org/10.1186/1477-7819-6-58
- Cutuli B (2007). Strategies in treating male breast cancer, Expert Opin Pharmacother, 8, 193-202. https://doi.org/10.1517/14656566.8.2.193
- Cutuli B, Lacroze M, Dilhuydy J, et al (1995). Male breast cancer: results of the treatments and prognostic factors in 397 cases, Eur J Cancer, 31A, 1960-4.
- Cutuli B, Borel C, Dhermain F, et al (2001). Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases, Radiother Oncol, 59, 247-55. https://doi.org/10.1016/S0167-8140(01)00337-1
- Daly B (2009). The impact of social roles on the experience of men in BRCA1/2 families: implications for counseling. J Genet Couns, 18, 42-8. https://doi.org/10.1007/s10897-008-9183-y
- Dicker P (2003). The safety and tolerability of low dose irradiation for the management of gynaecomastia caused by antdrogen monotherapy. Lancet Oncol, 4, 30-6. https://doi.org/10.1016/S1470-2045(03)00958-6
- Donegan W, Redlich P, Lang P, Gall M (1998). Carcinoma of the breast in males: a multiinstitutional survey. Cancer, 83, 498-509. https://doi.org/10.1002/(SICI)1097-0142(19980801)83:3<498::AID-CNCR19>3.0.CO;2-R
- Fisher B, Slack N, Katrych D, Wolmark N (1975), Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy, Surg Gynecol Obstet, 140, 528-34.
- Forloni F, Giovilli M, Pecis C, et al (2001). Pituitary prolactinsecreting macroadenoma combined with bilateral breast cancer in a 45-year-old male. J Endocrinol Invest, 24, 454-9. https://doi.org/10.1007/BF03351047
- Gancberg D, Di Leo A, Cardoso F, et al (2002), Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol, 13, 1036-43. https://doi.org/10.1093/annonc/mdf252
- Gennari R, Curigliano G, Jereczek-Fossa B, et al (2004). Male breast cancer: a special therapeutic problem. Anything new? Int J Oncol, 24, 663-70.
- Giordano S, Cohen D, Buzdar A, Perkins G, Hortobagyi G (2004). Breast carcinoma in men: a population-based study. Cancer, 101, 51-7. https://doi.org/10.1002/cncr.20312
- Giordano S, Perkins G, Broglio K, et al (2005). Adjuvant systemic therapy for male breast carcinoma. Cancer, 104, 2359-64. https://doi.org/10.1002/cncr.21526
- Handesman D (2001). Androgen action and pharmacologic uses. In Endocrinology, 2232-42, Eds Degroot A.
- Hooning M, Botma A, Aleman B, et al (2007). Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst, 99, 365-75. https://doi.org/10.1093/jnci/djk064
- Lanitis S, Rise J, Vaughan A, et al (2008). Diagnosis and management of male breast cancer. World J Surg, 32, 2471-76. https://doi.org/10.1007/s00268-008-9713-7
- Levy-Lahad E, Friedman E (2007). Cancer risks among BRCA1 and BRCA2 mutation carriers. BR J Cancer, 96, 11-5. https://doi.org/10.1038/sj.bjc.6603535
- Macdonald G, Paltiel C, Olivotto I, Tyldesley S (2005). A comparative analysis of radiotherapy use and patient outcome in males and females with breast cancer. Ann Oncol, 16, 1442-8. https://doi.org/10.1093/annonc/mdi274
- Mauras N, O'Brien K, Klein K, Hayes V (2000). Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab, 85, 2370-7. https://doi.org/10.1210/jc.85.7.2370
- Meijers-Heijboer H, Van den Ouweland A, Klijn J, et al (2002). CHEK2-Breast Cancer Consortium, Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet, 31, 55-9. https://doi.org/10.1038/ng879
- Mohamad B, Apffelstaedt P (2008). Counseling for male BRCA mutation carriers: a review. Breast, 17, 441-50. https://doi.org/10.1016/j.breast.2008.05.001
- Nahleh Z (2006), Hormonal therapy for male breast cancer: a different approach for a different disease, Cancer Treat Rev, 32, 101-5. https://doi.org/10.1016/j.ctrv.2005.12.007
- Nordenskjold, B Rosell J, Rutqvist L, et al (2005). Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial, J Natl Cancer Inst 97, 1609-10. https://doi.org/10.1093/jnci/dji342
- O'Malley C, Prehn A, Shema S, Glaser S (2002). Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer, 94, 2836-43. https://doi.org/10.1002/cncr.10521
- Ottini, Rizzolo, Zanna , et al (2009). BRCA1/BRCA2 mutation status and clinical pathologic features of 108 male breast cancer cases from Tuscany: a population based study in central Italy. Breast Cancer Res Treat, 116, 577-86. https://doi.org/10.1007/s10549-008-0194-z
- Ottini L, Palli P, Rizzo I, et al (2010). Male breast cancer. Crit Rev Oncol Hematol, 73, 141-55. https://doi.org/10.1016/j.critrevonc.2009.04.003
- Pant K, Dutta U (2008). Understanding and management of male breast cancer: a critical review. Med Oncol, 25, 294-98. https://doi.org/10.1007/s12032-007-9034-y
- Ribeiro G, Swindell R, Harris M, Banerjee S, Cramer A (1996). A review of the management of the male breast carcinoma based on an analysis of 420 treated cases. Breast, 5, 141-6. https://doi.org/10.1016/S0960-9776(96)90058-2
- Romond E, Perez E, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med, 353, 1673-84. https://doi.org/10.1056/NEJMoa052122
- Rossman E, Libjegren A, Bergh J (2007). Male breast cancerhow to treat? Breast Cancer on line, 10, 1-6. https://doi.org/10.4048/jbc.2007.10.1.1
- Smith I, Dowsett M, Ebbs S, et al (2005). Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate Preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol, 23, 5108-16. https://doi.org/10.1200/JCO.2005.04.005
- Smith I, Procter M, Gelber R, et al (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 369, 29-36. https://doi.org/10.1016/S0140-6736(07)60028-2
- Swerdlow A, Schoemaker M, Higgins C, et al (2005). Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst, 97, 1204-10. https://doi.org/10.1093/jnci/dji240
- Taber Johansen K, Moricy L, Osbahs A, Dickinson B (2010). Male breast cancer: risk factors, diagnosis and management. Oncology Reports, 24, 1115-20.
- Thellenberg C, Malmer B, Tavelin B, Gronberg H (2003). Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol, 169, 1345-48. https://doi.org/10.1097/01.ju.0000056706.88960.7c
- Trunet P, Mueller B, Bhatnagar A, et al (1993). Open dosefinding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab, 77, 319-23. https://doi.org/10.1210/jc.77.2.319
- Turner K, Morley M, Atanassova N, Swanston I, Sharpe R (2000). Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol, 164, 225-38. https://doi.org/10.1677/joe.0.1640225
- Vetto J, Jun S, Paduch D, Eppich A, Shih R (1999). Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg, 177, 379-83. https://doi.org/10.1016/S0002-9610(99)00067-7
- Willsher P, Leach I, Ellis I, et al (1997). A comparison outcome of male breast cancer with female breast cancer. Am J Surg, 173, 185-8. https://doi.org/10.1016/S0002-9610(97)89592-X
- Zabolotny B, Zalai C, Meterissian S (2005). Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol, 90, 26-30. https://doi.org/10.1002/jso.20233
피인용 문헌
- Columnar cell-like changes in the male breast vol.67, pp.1, 2014, https://doi.org/10.1136/jclinpath-2013-201631
- Male Breast Cancer Clinical Features, Risk Factors, and Current Diagnostic and Therapeutic Approaches vol.05, pp.17, 2014, https://doi.org/10.4236/ijcm.2014.517138
- Cancer Awareness among University Students in Turkey vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4289
- Male Breast Cancer: 20 Years Experience of a Tertiary Hospital from the Middle Black Sea Region of Turkey vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6673
- Hormone Receptor Expression and Clinicopathologic Features in Male and Female Breast Cancer vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.471
- Male Breast Cancer: a 24 Year Experience of a Tertiary Care Hospital in Pakistan vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1559
- Breast Cancer in Males (BCM), Does It Really Differ? National Cancer Institute Experience (NCI), Cairo University, Egypt vol.07, pp.05, 2016, https://doi.org/10.4236/jct.2016.75037
- Male breast cancer arising in ectopic axillary breast tissue: A diagnostic dilemma vol.5, pp.6, 2013, https://doi.org/10.3892/ol.2013.1300
- Male breast cancer: diagnosis stages, treatment and survival in a country with limited resources (Burkina Faso) vol.16, pp.1, 2018, https://doi.org/10.1186/s12957-017-1297-y
- Diagnosis and Treatment of Male Breast Tumors vol.08, pp.06, 2018, https://doi.org/10.12677/ACM.2018.86093